A survey has shown that UK doctors think AI can help them save time and expand their capacity to care for patients, but three ...

AI and connected data are reshaping feasibility and site selection across the clinical development lifecycle, allowing ...

For many years, body weight sat at the centre of obesity drug development. The knock-on effect of this was that clinical ...

EVERSANA has named Jen Norton as president of its Market Access & Value division, which helps life sciences companies secure ...

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy Nuvalent for $10.6 billion in a move that ...

AstraZeneca is preparing to move its oral GLP-1 agonist elecoglipron into a phase 3 programme in obesity and type 2 diabetes, after reporting encouraging mid-stage results. The results of the phase 2b ...

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug ...

This year, the transformation of China’s biotech and pharma industry into a dominant global player has only accelerated.

There was a similar picture in SYNCHRONIZE-MASLD, revealed for the first time at ADA and simultaneously published in Nature ...

Yesterday was National Cancer Survivors’ Day. At ASCO in Chicago last week, three cancer survivors shared parts of their ...

National Cancer Survivors’ Day highlighted decades of progress against cancer, but oncology faces a new challenge: with ...

Alongside the weight-loss result, however, were significant improvements in knee osteoarthritis pain, with an improvement of ...